Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.

Novel telemedicine approach helps HNC survivors deal with body image issues

19 May 2020
The elderly, especially, can benefit from most from telemedicine.

A novel telemedicine-based cognitive-behavioural intervention may help manage body image disturbances (BIDs) in survivors of head and neck cancer (HNC), a new study reveals.

The study included 10 HNC survivors with Body Image Scale-determined BID. They underwent intervention using the BRIGHT* tool, which consisted of five weekly hour-long sessions delivered through a tablet. Assessments were performed at baseline and at 1 and 3 months after BRIGHT. Semi-structured interviews were also conducted to determine the feasibility and acceptability of the intervention.

One patient was lost to follow-up. The remaining nine patients successfully completed the course and were included in the subsequent analysis.

All but one of the participants moderately or strongly agreed that starting the programme a month after HNC treatment worked well. The same number of positive responses was earned for the use of telemedicine as a method of delivery. Satisfaction was likewise high, with 89 percent saying that they were likely to recommend BRIGHT to other HNC survivors.

Notably, a month after BRIGHT, eight of the nine remaining participants experienced a reduction in BID severity. By 3 months post-BRIGHT, this effect was true for all survivors. At the respective time points, Body Image Scales scores dropped by 4.56 and 3.56 points relative to baseline.

Moreover, the semi-structured interviews also showed that BRIGHT helped improve image coping behaviours.

*Building a Renews Image after Head and Neck Cancer Treatment

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 13 Jul 2020

An MRI-first diagnostic pathway, combined with risk-tailored screening, is shown to improve the benefit-to-harm profile and cost-effectiveness of screening for prostate cancer (PCa), according to results of a recent lifetable modelling study presented at AACR 2020 Virtual Meeting II.

Christina Lau, 14 Jul 2020

Flat-dose nivolumab, administered as a 30-minute infusion, is well tolerated and active in Asian patients with previously treated advanced non-small-cell lung cancer (NSCLC), according to results of the phase IIIb CheckMate 870 study.

Natalia Reoutova, 17 Jul 2020

At a median follow-up of 22.9 months, atezolizumab plus carboplatin and etoposide (CP/ET), given as a first-line treatment, continued to demonstrate an improvement in overall survival (OS) vs placebo plus CP/ET in patients with extensive-stage small-cell lung cancer (ES-SCLC), according to updated results of the IMpower133 trial presented at the American Association for cancer Research (AACR) 2020 Virtual Annual Meeting II.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.